Melatonin as a Supplement Ingredient: What Brands Need to Know Before They Formulate

The sleep supplement category has gone through a significant expansion in the last few years. What used to be a relatively straightforward shelf (melatonin tablets at a few dosage levels) has evolved into one of the more complex formulation landscapes in the functional ingredients space. Gummies, sublingual sprays, fast-dissolve strips, extended-release tablets, multi-ingredient blends, and functional beverage additions have all entered the market, each requiring different raw material specifications and formulation approaches.

For brands entering or expanding in this space, the decisions made early in product development tend to stick. How much melatonin you put in, what format you choose, and where you source the ingredient all affect what ends up on the label, how the product actually works, and which markets you can sell into without hitting regulatory walls.

This article covers the ground floor: what melatonin does as a supplement ingredient, the key raw material specifications, how dosage choices interact with different delivery formats, and the market context that's shaping where the category is heading.

What melatonin does and why the dosage range matters so much

Melatonin is a hormone naturally produced by the pineal gland, released in response to darkness to signal the body that it's time to wind down. As a supplement ingredient, it supports the body's natural sleep-wake cycle, helping with sleep onset, adjusting to new time zones, and supporting shift workers whose schedules run against natural light patterns.

The dosage question is where most brands make their first significant formulation decision, and it's worth spending some time on because the range in commercial products is unusually wide. Products on the market run from 0.1mg up to 10mg per serving, and the choice of where to sit in that range affects both the consumer experience and the regulatory position in key markets.

Low doses, roughly 0.1mg to 0.5mg, are closer to what the body produces on its own rather than a significant top-up. This range is gaining ground in Europe where several countries cap supplement doses conservatively, and it fits well with brands positioning around "gentle support" or "wake up feeling fresh" messaging. The tradeoff is that the effect can be harder for consumers to notice, so the product story needs to do more work.

Mid-range doses from 1mg to 3mg are the most common in commercially successful sleep supplement products globally. The 1mg level is significant for the European market specifically: the European Food Safety Authority (EFSA) has approved health claims for melatonin at 1mg for reducing sleep onset time and at 0.5mg for alleviating jet lag. These are the only two claims that can legally appear on supplement labels across EU markets, which makes 1mg a practical anchor point for brands targeting Europe.

Higher doses from 5mg to 10mg dominate the North American market and appear frequently in products targeting consumers with more significant sleep difficulties. The US has no mandated upper limit for melatonin supplements, which has allowed the market to develop around whatever dose sells, and that ceiling has trended upward over time. Whether higher doses produce better outcomes for the average consumer is genuinely debated, but from a product development perspective, higher doses give brands more latitude on labeling claims in markets that allow them.

Raw material specifications: what to look for when sourcing

Supplement-grade melatonin is made synthetically. Despite what some labels suggest with phrasing like "natural melatonin," the ingredient in commercial supplements is lab-produced. The molecule is the same as what the body makes, but it's not extracted from a plant or animal source. This is completely standard and not a quality issue, but it does mean that "natural source" claims don't hold up for the raw ingredient itself. Brands can still position the overall product naturally, just not the melatonin specifically.

For raw material procurement, the key specification parameters are:

Purity. The standard for supplement-grade melatonin is ≥99% by HPLC. When you're reviewing a COA, look for the testing method and whether related impurities are listed individually. Synthesis can produce a handful of similar compounds alongside the main ingredient, so a breakdown of what else is in there tells you more than a single purity number.

Appearance and solubility. Melatonin is a white to off-white crystalline powder. It is practically insoluble in water at room temperature, which has significant implications for certain delivery formats, particularly beverages and liquid formulations where dissolution needs to be addressed through formulation design rather than assumed.

Heavy metals and microbiological testing. A proper COA should cover lead, arsenic, mercury, cadmium, total plate count, yeast and mold, and pathogen screening. For EU markets, these panels aren't optional; they're the entry ticket, and regulators in several countries have been paying closer attention to supplement quality lately.

Stability data. Melatonin is sensitive to light and heat degradation. Ask suppliers for stability data under accelerated conditions, and confirm packaging recommendations; light-protective packaging is standard for reasons that extend beyond aesthetics.

Delivery formats and what changes across each

The delivery format decision interacts with raw material specification in ways that aren't always obvious at the outset.

Tablets and capsules remain the dominant category, holding around 54% of global market volume. They allow precise dosing, support controlled-release formulations, and are straightforward to manufacture. For brands where clinical credibility and dosing precision are central to the positioning, this is still the default format.

Extended-release tablets deserve a separate mention. They're more complex to manufacture but address a different consumer complaint than immediate-release: immediate-release helps with falling asleep, while extended-release targets waking during the night. The bilayer tablet format, which combines an immediate-release layer for sleep onset with an extended-release layer for sleep maintenance, is growing quickly and commands a meaningful price premium. The raw material specification is the same, but the manufacturing process requires additional formulation work.

Gummies have emerged as the category's fastest-growing format, now capturing around 38–39% of new product launches. The consumer appeal is clear: taste, convenience, and no pill-swallowing. The tricky part is dosing consistency. Gummies are harder to dose accurately than capsules or tablets, and the cooking process involves heat and acidity that can knock out some of the active ingredient if the process isn't dialed in. For melatonin this is workable, but it does mean you need to test the finished product rather than assume the labeled dose made it through production intact.

Liquid drops and sublingual formats are a smaller but growing segment, particularly in pediatric and geriatric applications where swallowing solid doses is an issue. Melatonin's poor water solubility needs to be addressed in liquid formulations, typically through co-solvents or solubilizing agents, and the format needs light-protective packaging and preservative systems for shelf stability.

Functional beverages and food applications are a separate topic that warrants its own treatment, but the short version is that melatonin's water solubility limitation and its sensitivity to the processing conditions common in beverage manufacturing require specific solutions that go beyond what works in capsule or tablet formats, whether that's encapsulation, solubilization technology, or careful pH and temperature control.

The market context shaping where brands are investing

A few trends worth noting for brands making formulation and sourcing decisions now:

Gummies continue to take share from tablets and capsules among younger demographics, and brands without a gummy SKU are increasingly at a disadvantage in mass retail. Around 46% of consumers now indicate a preference for plant-derived or natural-labeled melatonin products, which is driving demand for clean-label formulations and putting pressure on brands to be more precise about their sourcing and processing claims.

Asia-Pacific is the fastest-growing region, driven by urbanization and a growing consumer awareness around sleep health that's still relatively early-stage compared to North America or Europe. Southeast Asian markets in particular are moving quickly across the whole functional supplement space, and melatonin is a natural fit as awareness builds.

Multi-ingredient and extended-release formats are pulling ahead of basic single-ingredient products. A standalone melatonin tablet at a fixed dose is increasingly a commodity play, while blended formulas and differentiated delivery formats give brands more room to hold price and tell a better product story.

At Sheerherb, we supply melatonin powder ≥99% purity with full COA documentation, suitable for tablet, capsule, gummy, and powder-format applications. If you're developing a new sleep product or evaluating your current raw material source, we're happy to provide samples alongside technical documentation. Contact us at chriswang@sheerherb.com with your target format and market.

References